 |
 |
||||||||||
 |
 |
 |
 |
 |
 |
||||||
 |
|
|
|
|
|
|
|
|
|
|
|
Overview of the 2009 event
|
George Muschler, MD, discussing this year's event |
The Cleveland Clinic Orthopaedic and Rheumatology Institute hosted the Quality Innovation Summit 2009 on May 13-15 at the InterContinental Hotel in Cleveland, Ohio.
The Summit was a unique event that explored the state of the art in the assessment and management of quality in musculoskeletal medicine by integrating the perspectives of the key stakeholders, including patients, physicians, institutions, professional societies, public and private payers, regulatory agencies, nongovernment organizations, patient safety organizations, device and pharmaceutical industries, funding entities, and state and federal regulatory agencies.
Participants were given the opportunity to understand the common and competing interests and visions shaping the assessment of quality in musculoskeletal medicine. The overriding goal was to identify quality assessment practices that effectively measure patient outcomes and that meet the aligned interests of stakeholders, which ultimately, will improve patient care, value, and outcomes.
A renowned faculty provided overviews and lead discussions on a number of timely and pertinent topics. These include basic principles and methods of quality assessment and management; the varied perspectives of quality from individual stakeholders; current tools for quality assessment; challenges and barriers to advancing quality over the long term; and the evolving clinical, institutional, business, and governmental strategies that will drive the future of quality and performance measures.
| The project described was supported by Award Number R13AR057264 from the National Institute Of Arthritis And Musculoskeletal And Skin Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Arthritis And Musculoskeletal And Skin Diseases or the National Institutes of Health. |
Objectives
- Define the core principles and terminology for assessment and management of quality in musculoskeletal disorders;
- Discuss the quality metrics and management tools available to measure quality outcomes;
- Describe the current best practice models in the assessment and management of quality from the perspective of each stakeholder;
- Identify points of synergy and tension regarding quality assessment in the perspectives of patients, physicians, institutions, third-party payers, regulatory agencies, industry, and government and nongovernment agencies associated with management of musculoskeletal disorders;
- Compare and contrast the opportunities for advancing musculoskeletal care and cost effectiveness through collaborative programs in quality assessment and management extending across the various stakeholder domains.
Target Audience
This Summit was an integrated forum for discoveries and networking among clinicians, scientists, health institutions, public and private third-party payers, biomedical industry, and government and nongovernment organizations that share an interest in understanding, promoting, and shaping the future of quality assessment and management practices in musculoskeletal medicine.
